Skip to content

Compare

Qsymia vs Contrave

Quick read · 5 min

Last reviewed: September 2026Based on 2 clinical trialsEvery claim linked to source

Qsymia (phentermine / topiramate ER, daily capsule) and Contrave (naltrexone / bupropion ER, twice-daily tablet) are both approved for weight loss in the United States. No head-to-head trial has compared these two drugs. The figures below come from separate trials, each with its own participants, length and comparison group.

At a glance

Qsymia and Contrave compared on form, trial results, cost and reported side effects
 QsymiaContrave
FormDaily capsuleTwice-daily tablet
How oftenDaily oral capsule — no injectionTwice-daily oral tablet — no injection
Weight loss in trialsUp to 9.8% — CONQUER (56 weeks)Up to 9.3% — COR-BMOD (56 weeks)
FDA approved20122014
Made byVivusCurrax Pharmaceuticals
How it worksPhentermine suppresses appetite by triggering the release of adrenaline-like chemicals in the brain's hunger control centre.Bupropion activates appetite-suppressing nerve cells in the brain's hunger control centre (the hypothalamus).
Monthly cost, self-pay$30–$400/mogeneric; brand runs to $400$100–$400/mo
Most reported reactionDry mouth 21% (CONQUER)Nausea 33% (COR-I)

Every figure in this table is read from the same trial and label records used everywhere else on this site.

Weight loss in each drug's main trial

No head-to-head trial has compared these two drugs.

Qsymia(phentermine / topiramate ER)9.8%

CONQUER (56 weeks)

Contrave(naltrexone / bupropion ER)9.3%

COR-BMOD (56 weeks)

In clinical trials, participants taking phentermine / topiramate ER lost on average up to 9.8% of their starting body weight, and participants taking naltrexone / bupropion ER lost on average up to 9.3%. Those numbers come from two different studies: CONQUER enrolled 2,487 adults with obesity and at least 2 weight-related health conditions over 56 weeks against placebo, while COR-BMOD enrolled adults with obesity, with intensive behaviour therapy over 56 weeks against placebo + intensive behaviour therapy. Who took part, how long each trial ran and what each drug was measured against all move the percentage, so the two figures are not a measured difference between the drugs.

Monthly cost, self-pay

The bar spans the range in each drug's price record — lowest listed price to highest.

Qsymia$30–$400/mo

generic; brand runs to $400

~$30–$80/month generic; ~$200–$400/month brand (Qsymia).

Contrave$100–$400/mo

~$100–$400/month (brand). Generic available in some markets.

Self-pay prices are what the manufacturer or the pharmacy lists, not what most people end up paying. Qsymia: $30–$400/month. Contrave: $100–$400/month. Insurance, dose and pharmacy all change both figures.

Side effects reported in the trials

Both trials reported 3 reactions in common. Each rate is the percentage of participants who reported it in the trial named beside it, so the two columns are not from the same study.

Dry mouth
Qsymia · CONQUER21%
Contrave · COR-I8%
Constipation
Qsymia · CONQUER17%
Contrave · COR-I19%
Dizziness
Qsymia · CONQUER9%
Contrave · COR-I10%

A rate is the share of trial participants who reported that reaction, not a prediction for any one person.

How they differ in practice

How you take it

  • QsymiaOnce-daily extended-release capsule
  • ContraveOral extended-release tablet, twice daily

Dose build-up

  • Qsymia3.75/23 mg → 15/92 mg, titrated over 14 weeks
  • Contravetitrated to 32/360 mg/day over 4 weeks

Where a drug is not listed here, its prescribing information sets out its own dose steps.

How soon it acts

  • QsymiaAppetite suppression typically begins within the first week; significant weight loss by 12–16 weeks
  • ContraveAppetite and craving changes typically within 4–8 weeks; significant weight loss by 16–24 weeks

Heart and metabolic findings

  • QsymiaIn CONQUER, significant reductions in blood pressure, waist circumference, triglycerides, and blood glucose were observed.
  • ContraveThe LIGHT cardiovascular outcomes trial was terminated early due to a protocol violation and did not provide a definitive answer on CV outcomes.

As stated in each drug’s trial record — not a claim about which drug protects the heart more.

Other findings recorded

  • QsymiaGeneric now available (from 2025) — significantly lower cost than GLP-1 drugs; improved blood pressure and triglycerides in CONQUER trial
  • ContraveMay help specifically with emotional eating and food cravings; bupropion's antidepressant effect may be beneficial if low mood contributes to overeating

If you stop taking it

  • QsymiaWeight regain after stopping is expected.
  • ContraveWeight regain after stopping is expected.

Common questions

Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice

How this site is built →

Next step most people take

Built with agentic AI tools and not a substitute for medical advice

Last reviewed:

Medical disclaimer: This website is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment.